JP2019513748A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513748A5 JP2019513748A5 JP2018552804A JP2018552804A JP2019513748A5 JP 2019513748 A5 JP2019513748 A5 JP 2019513748A5 JP 2018552804 A JP2018552804 A JP 2018552804A JP 2018552804 A JP2018552804 A JP 2018552804A JP 2019513748 A5 JP2019513748 A5 JP 2019513748A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fxii
- subject
- pharmaceutical composition
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022084909A JP2022116154A (ja) | 2016-04-06 | 2022-05-25 | アテローム性動脈硬化症の治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16164009.9 | 2016-04-06 | ||
| EP16164009 | 2016-04-06 | ||
| PCT/AU2017/050297 WO2017173494A1 (en) | 2016-04-06 | 2017-04-06 | Method of treating atherosclerosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022084909A Division JP2022116154A (ja) | 2016-04-06 | 2022-05-25 | アテローム性動脈硬化症の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019513748A JP2019513748A (ja) | 2019-05-30 |
| JP2019513748A5 true JP2019513748A5 (enExample) | 2020-05-07 |
| JP7456723B2 JP7456723B2 (ja) | 2024-03-27 |
Family
ID=55759460
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018552804A Active JP7456723B2 (ja) | 2016-04-06 | 2017-04-06 | アテローム性動脈硬化症の治療方法 |
| JP2022084909A Pending JP2022116154A (ja) | 2016-04-06 | 2022-05-25 | アテローム性動脈硬化症の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022084909A Pending JP2022116154A (ja) | 2016-04-06 | 2022-05-25 | アテローム性動脈硬化症の治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11174321B2 (enExample) |
| EP (1) | EP3440107A4 (enExample) |
| JP (2) | JP7456723B2 (enExample) |
| KR (2) | KR20230136687A (enExample) |
| CN (1) | CN109071629A (enExample) |
| AU (2) | AU2017247004B2 (enExample) |
| CA (1) | CA3019851A1 (enExample) |
| WO (1) | WO2017173494A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014135694A1 (en) | 2013-03-08 | 2014-09-12 | Csl Behring Ag | Treatment and prevention of remote ischemia-reperfusion injury |
| DK3157548T3 (da) | 2014-06-18 | 2021-09-06 | Csl Behring Gmbh | Terapi anvendelse af en faktor xii-inhibitor i en neurotraumatisk sygdom |
| EP3440107A4 (en) * | 2016-04-06 | 2020-02-19 | CSL Limited | METHOD FOR TREATING ATHEROSCLEROSIS |
| WO2019113642A1 (en) * | 2017-12-15 | 2019-06-20 | Csl Limited | Use of a fxiia-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease |
| KR20220019806A (ko) * | 2019-06-12 | 2022-02-17 | 씨에스엘 이노베이션 피티와이 엘티디 | 가용성 보체 수용체 1형 변이체 접합체 및 이의 용도 |
| IL293512A (en) * | 2019-12-03 | 2022-08-01 | CSL Innovation Pty Ltd | Use of an anti-factor xii antibody for the treatment or prevention of hereditary angioedema |
| IL298989A (en) * | 2020-07-03 | 2023-02-01 | CSL Innovation Pty Ltd | High concentration promotion of factor XII antigen binding proteins |
| WO2022235551A2 (en) * | 2021-05-03 | 2022-11-10 | President And Fellows Of Harvard College | Fc-fusion protein therapeutic for the treatment of pancreatitis |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| US4963657A (en) * | 1988-06-09 | 1990-10-16 | Temple University Of The Commonwealth System Of Higher Education | Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| AU1674292A (en) | 1991-03-15 | 1992-10-21 | Synergen, Inc. | Pegylation of polypeptides |
| CA2205572A1 (en) | 1994-12-12 | 1996-06-20 | Beth Israel Hospital Association | Chimeric cytokines and uses thereof |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6926898B2 (en) | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| AU2003210806A1 (en) | 2002-03-05 | 2003-09-22 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| SI1624891T2 (sl) | 2003-05-06 | 2013-09-30 | Biogen Idec Hemophilia Inc. | Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| ES2371072T3 (es) | 2003-06-12 | 2011-12-27 | Eli Lilly And Company | Proteínas de fusión análogas de glp-1. |
| AU2004271200A1 (en) | 2003-09-05 | 2005-03-17 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
| EP1699821B1 (en) | 2003-12-31 | 2012-06-20 | Merck Patent GmbH | Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS |
| JP4958555B2 (ja) | 2004-09-22 | 2012-06-20 | 協和発酵キリン株式会社 | 安定化されたヒトＩｇＧ４抗体 |
| CN101102819A (zh) * | 2004-12-23 | 2008-01-09 | Csl百灵有限公司 | 血栓的形成和/或稳定化的预防 |
| GB0607515D0 (en) * | 2006-04-13 | 2006-05-24 | Axis Shield Diagnostics Ltd | Anti-factor xlla therapy |
| DK2109457T3 (en) | 2007-02-12 | 2016-04-11 | Csl Behring Gmbh | THERAPEUTIC USE OF KAZAL TYPE SERINE PROTEASE INHIBITORS |
| JP5734201B2 (ja) | 2008-12-19 | 2015-06-17 | マクロジェニクス，インコーポレーテッド | 共有結合型ダイアボディ及びその使用 |
| LV14606B (lv) | 2011-05-17 | 2013-01-20 | Tetra, Sia | Jauns XII faktora inhibitors |
| HRP20250164T1 (hr) | 2011-07-22 | 2025-04-11 | Csl Behring Gmbh | Inhibitorna monoklonska antitijela protiv faktora xii/xiia i njihove uporabe |
| JP5653860B2 (ja) * | 2011-07-28 | 2015-01-14 | 富士フイルム株式会社 | 管壁の硬度測定方法および装置 |
| EP2623110A1 (en) | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
| WO2014135694A1 (en) | 2013-03-08 | 2014-09-12 | Csl Behring Ag | Treatment and prevention of remote ischemia-reperfusion injury |
| CA2916399C (en) * | 2013-06-28 | 2022-08-02 | Marc Nolte | Combination therapy using a factor xii inhibitor and a c1-inhibitor |
| DK3157548T3 (da) | 2014-06-18 | 2021-09-06 | Csl Behring Gmbh | Terapi anvendelse af en faktor xii-inhibitor i en neurotraumatisk sygdom |
| EP3440107A4 (en) * | 2016-04-06 | 2020-02-19 | CSL Limited | METHOD FOR TREATING ATHEROSCLEROSIS |
-
2017
- 2017-04-06 EP EP17778478.2A patent/EP3440107A4/en active Pending
- 2017-04-06 KR KR1020237031602A patent/KR20230136687A/ko not_active Ceased
- 2017-04-06 KR KR1020187032136A patent/KR20180132831A/ko not_active Ceased
- 2017-04-06 CN CN201780022190.9A patent/CN109071629A/zh active Pending
- 2017-04-06 CA CA3019851A patent/CA3019851A1/en active Pending
- 2017-04-06 WO PCT/AU2017/050297 patent/WO2017173494A1/en not_active Ceased
- 2017-04-06 AU AU2017247004A patent/AU2017247004B2/en active Active
- 2017-04-06 US US16/090,861 patent/US11174321B2/en active Active
- 2017-04-06 JP JP2018552804A patent/JP7456723B2/ja active Active
-
2021
- 2021-10-11 US US17/498,112 patent/US20220017638A1/en not_active Abandoned
-
2022
- 2022-05-25 JP JP2022084909A patent/JP2022116154A/ja active Pending
- 2022-10-04 AU AU2022241636A patent/AU2022241636B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2935419T3 (es) | Constructos de anticuerpo biespecíficos para PSMA y CD3 que se ligan a células T | |
| IL323633A (en) | Humanized anti-kallikrein-2 antibody | |
| CN104968361B (zh) | 用于治疗或预防疾病的因子1蛋白、因子2蛋白及其抑制剂 | |
| AU2020307471A1 (en) | Dosing regimen and combination therapies for multispecific antibodies targeting B-cell maturation antigen | |
| BR112019022751A2 (pt) | composição farmacêutica compreendendo construtos de anticorpos biespecíficos para armazenamento e administração melhorados | |
| KR20150080033A (ko) | 골관절염 및 통증의 치료 방법 | |
| JP2013516389A (ja) | カリクレイン阻害剤による粘膜炎治療 | |
| JP2025102888A (ja) | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 | |
| CN103958542A (zh) | 经修饰的白蛋白结合结构域及其用于改善药代动力学的用途 | |
| KR20210086671A (ko) | 항-vegf 항체 및 항-조직 인자 항체-약물 접합체의 조합을 사용하여 암을 치료하는 방법 | |
| US20150203592A1 (en) | Compositions and methods for treating osteoarthritis | |
| JP2023138982A (ja) | インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を治療する方法 | |
| JP2017524675A5 (enExample) | ||
| JP2023501276A (ja) | Ｈｌａ－ａ２／ｗｔ１×ｃｄ３二重特異性抗体及びレナリドマイドを使用するがんの治療 | |
| US20220119538A1 (en) | Anti-il-36r antibodies for treatment of chronic inflammatory pain | |
| JP2024537284A (ja) | 抗ｎｐｒ１抗体を投与することにより血行動態の変化を引き起こす方法 | |
| GB2520353A (en) | Antibody polypeptides and uses thereof | |
| US11952416B2 (en) | Anti-annexin A1 antibodies | |
| CN102015768A (zh) | 与ed-b纤连蛋白特异性结合的放射性标记分子在治疗霍奇金淋巴瘤的方法中的用途 | |
| US20240228666A1 (en) | Therapeutic methods and uses for antibodies to human masp-3 | |
| JP2019505516A (ja) | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 | |
| WO2024031049A2 (en) | Pharmaceutical compositions of fusion proteins and methods of use thereof | |
| WO2025094976A1 (ja) | ヘモジデリンの沈着及び／又は滑膜肥厚の改善又は抑制剤 | |
| WO2021207667A1 (en) | Compositions and methods for treating lung injury or acute respiratory distress syndrome (ards) | |
| CN120437287A (zh) | 一种包含特异性结合gucy2c和cd3的双特异性抗体的药物组合物 |